2021
Variability in Blood Pressure Assessment in Patients Supported with the HeartMate 3TM
Cowger JA, Estep JD, Rinde-Hoffman DA, Givertz MM, Anderson AS, Jacoby D, Chen L, Brieke A, Mahr C, Hall S, Ewald GA, Dirckx N, Baker AT, Pinney SP. Variability in Blood Pressure Assessment in Patients Supported with the HeartMate 3TM. ASAIO Journal 2021, 68: 374-383. PMID: 34172641, DOI: 10.1097/mat.0000000000001497.Peer-Reviewed Original ResearchMeSH KeywordsBlood PressureBlood Pressure DeterminationHeart RateHeart-Assist DevicesHumansUltrasonography, DopplerConceptsDoppler opening pressureSystolic blood pressureRadial pulsePalpable radial pulseBlood pressure controlBlood pressure assessmentHeartMate 3 patientsCuff measuresMedication titrationPalpable pulseBlood pressureMean arterialMedical managementPulse pressureBP valuesPressure assessmentPressure controlPatientsOpening pressureMmHgModerate correlationNoninvasive measurementNoninvasive instrumentPearson correlationOutpatientsClinical characteristics and outcomes in childhood-onset hypertrophic cardiomyopathy
Marston NA, Han L, Olivotto I, Day SM, Ashley EA, Michels M, Pereira AC, Ingles J, Semsarian C, Jacoby D, Colan SD, Rossano JW, Wittekind SG, Ware JS, Saberi S, Helms AS, Ho CY. Clinical characteristics and outcomes in childhood-onset hypertrophic cardiomyopathy. European Heart Journal 2021, 42: 1988-1996. PMID: 33769460, PMCID: PMC8139852, DOI: 10.1093/eurheartj/ehab148.Peer-Reviewed Original ResearchMeSH KeywordsAdultAtrial FibrillationCardiomyopathy, HypertrophicHeart FailureHeart-Assist DevicesHumansRegistriesConceptsChildhood-onset hypertrophic cardiomyopathyLife-threatening ventricular arrhythmiasHeart failureHypertrophic cardiomyopathyAtrial fibrillationVentricular arrhythmiasComposite endpointHCM patientsRisk of HFSarcomeric Human Cardiomyopathy RegistryNatural historyAdvanced HF therapiesOverall composite outcomeObservational cohort studyClinical risk stratificationHypertrophic cardiomyopathy patientsAge of diagnosisVentricular assist deviceAdult-onset diseaseHF therapyClinical characteristicsCohort studyComposite outcomeBaseline visitRisk stratificationChanges in Use of Left Ventricular Assist Devices as Bridge to Transplantation With New Heart Allocation Policy
Mullan CW, Chouairi F, Sen S, Mori M, Clark KAA, Reinhardt SW, Miller PE, Fuery MA, Jacoby D, Maulion C, Anwer M, Geirsson A, Mulligan D, Formica R, Rogers JG, Desai NR, Ahmad T. Changes in Use of Left Ventricular Assist Devices as Bridge to Transplantation With New Heart Allocation Policy. JACC Heart Failure 2021, 9: 420-429. PMID: 33714748, DOI: 10.1016/j.jchf.2021.01.010.Peer-Reviewed Original ResearchMeSH KeywordsAdultHeart FailureHeart TransplantationHeart-Assist DevicesHumansPolicyRetrospective StudiesTissue DonorsTreatment OutcomeUnited StatesWaiting ListsConceptsDonor heart allocation systemNumber of patientsHeart allocation systemVentricular assist deviceWaitlist survivalAssist deviceNew heart allocation policyLeft ventricular assist deviceAllocation system changePost-transplant mortalityOrgan Sharing databaseOutcomes of patientsPost-transplantation outcomesProportion of patientsTime of transplantContinuous-flow LVADPost-transplantation survivalHeart allocation policyNew allocation systemBaseline recipientStatus 1AHeart transplantationIschemic timeLVAD implantationTransplant list
2020
Impact of Preoperative Lymphopenia on Survival Following Left Ventricular Assist Device Placement
Stawiarski K, Agboola O, Park J, Geirsson A, Jacoby D, Bellumkonda L, Ahmad T, Chou J, Lee F, Mangi A, Bonde P. Impact of Preoperative Lymphopenia on Survival Following Left Ventricular Assist Device Placement. ASAIO Journal 2020, 67: 650-657. PMID: 33074860, DOI: 10.1097/mat.0000000000001289.Peer-Reviewed Original ResearchMeSH KeywordsAgedFemaleHeart FailureHeart-Assist DevicesHumansLymphopeniaMaleMiddle AgedProportional Hazards ModelsConceptsAbsolute lymphocyte countCause mortalityLymphopenia groupLeft ventricular assist device patientsVentricular assist device patientsVentricular assist device placementCox proportional hazards modelImpact of lymphopeniaHeart failure populationKaplan-Meier plotsFurther clinical investigationProportional hazards modelLog-rank statisticsDurable LVADPreoperative lymphopeniaLVAD placementLymphocyte countLymphopenic patientsDevice patientsSingle centerPoor outcomePrognostic implicationsALC levelsFailure populationStudy populationAssociation of Obesity With Adverse Long-term Outcomes in Hypertrophic Cardiomyopathy
Fumagalli C, Maurizi N, Day SM, Ashley EA, Michels M, Colan SD, Jacoby D, Marchionni N, Vincent-Tompkins J, Ho CY, Olivotto I. Association of Obesity With Adverse Long-term Outcomes in Hypertrophic Cardiomyopathy. JAMA Cardiology 2020, 5: 65-72. PMID: 31693057, PMCID: PMC6865784, DOI: 10.1001/jamacardio.2019.4268.Peer-Reviewed Original ResearchMeSH KeywordsAdultArrhythmias, CardiacAtrial FibrillationBody Mass IndexCardiomyopathy, HypertrophicCohort StudiesDeath, Sudden, CardiacDefibrillators, ImplantableDisease ProgressionElectric CountershockFemaleHeart ArrestHeart FailureHeart TransplantationHeart-Assist DevicesHumansMaleMiddle AgedMortalityObesityRetrospective StudiesStrokeStroke VolumeVentricular Outflow ObstructionConceptsOverall composite outcomeLong-term outcomesHypertrophic cardiomyopathyComposite outcomeObstructive physiologyAdverse outcomesSarcomeric Human Cardiomyopathy RegistryAdverse long-term outcomesLong-term adverse outcomesLife-threatening ventricular arrhythmiasHeart failure outcomesHeart failure symptomsAssociation of obesityDisease-related complicationsNormal weight groupBody mass indexOverall disease progressionBody weight increaseHCM centersAtrium diameterBaseline BMIObesity groupCardiovascular mortalityCohort studyMass indexAssociation of Race With Disease Expression and Clinical Outcomes Among Patients With Hypertrophic Cardiomyopathy
Eberly LA, Day SM, Ashley EA, Jacoby DL, Jefferies JL, Colan SD, Rossano JW, Semsarian C, Pereira AC, Olivotto I, Ingles J, Seidman CE, Channaoui N, Cirino AL, Han L, Ho CY, Lakdawala NK. Association of Race With Disease Expression and Clinical Outcomes Among Patients With Hypertrophic Cardiomyopathy. JAMA Cardiology 2020, 5: 83-91. PMID: 31799990, PMCID: PMC6902181, DOI: 10.1001/jamacardio.2019.4638.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAtrial FibrillationBlack or African AmericanCardiomyopathy, HypertrophicCohort StudiesDeath, Sudden, CardiacDefibrillators, ImplantableFemaleGenetic TestingHealth Services AccessibilityHealthcare DisparitiesHeart FailureHeart SeptumHeart TransplantationHeart-Assist DevicesHumansMaleMiddle AgedMortalityPhenotypeQuality of Health CareStrokeUnited StatesWhite PeopleConceptsNYHA class IIIAssociation of raceVentricular assist device implantationOverall composite outcomeSeptal reduction therapyAssist device implantationHeart failureBlack patientsHypertrophic cardiomyopathyCause mortalityWhite patientsAtrial fibrillationClass IIICardiac transplantationGenetic testingComposite outcomeClinical outcomesDisease expressionDevice implantationReduction therapyNew York Heart Association functional class IIIMultivariable Cox proportional hazards regressionInvasive septal reduction therapySarcomeric Human Cardiomyopathy RegistryImplantable cardioverter-defibrillator therapy